Profile data is unavailable for this security.
About the company
Oxford BioDynamics Plc is a United Kingdom-based biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases. The Company is primarily engaged in the commercialization of proprietary molecular diagnostics products and biomarker research and development. Its products include EpiSwitch CiRT, EpiSwitch PSE, Specimen Submission Kit, and EpiSwitch Explorer. The EpiSwitch CiRT is a blood test which predicts an individual patient’s therapeutic response to checkpoint inhibitor immunotherapy. The EpiSwitch Explorer is a microarray kit for high-throughput, high-resolution 3D genome profiling. The Specimen Submission Kit is used for collecting samples from any location. The EpiSwitch platform offers reproducibly translating three-dimensional (3D) genome regulation for clinical applications. This platform provides a portfolio of clinical smart tests based on EpiSwitch technology.
- Revenue in GBP (TTM)1.10m
- Net income in GBP-11.15m
- Incorporated2007
- Employees44.00
- LocationOxford Biodynamics PLC26 Beaumont StreetOXFORD OX4 2WBUnited KingdomGBR
- Phone+44 186 551 8910
- Fax+44 186 551 1418
- Websitehttps://www.oxfordbiodynamics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Probiotix Health PLC | 2.22m | -736.00k | 12.26m | 4.00 | -- | 6.85 | -- | 5.52 | -0.005 | -0.005 | 0.0146 | 0.0113 | 1.05 | 18.57 | 3.01 | 555,250.00 | -34.67 | -21.03 | -46.17 | -27.30 | 53.17 | 54.10 | -33.14 | -26.58 | 3.99 | -- | 0.00 | -- | 12.55 | 36.47 | -13.39 | -- | -41.50 | -- |
| Cosma SA | 2.67m | -4.82m | 12.28m | 30.00 | -- | 5.74 | -- | 4.60 | -0.1635 | -0.1635 | 0.0934 | 0.0683 | 0.435 | 2.14 | 6.00 | 517,444.00 | -78.50 | -- | -100.47 | -- | 50.66 | -- | -180.44 | -- | 0.4173 | -92.62 | 0.2326 | -- | 173.51 | -- | 42.40 | -- | -- | -- |
| IRLAB Therapeutics AB | 7.03m | -7.55m | 12.79m | 31.00 | -- | 2.88 | -- | 1.82 | -1.56 | -1.56 | 1.40 | 0.6382 | 0.5172 | -- | 8.93 | 3,168,815.00 | -55.56 | -27.34 | -149.51 | -32.01 | -35.80 | -45.70 | -107.43 | -112.19 | -- | -4.29 | 0.3548 | -- | 1,566.57 | 415.48 | 53.26 | -- | 7.75 | -- |
| CASI Pharmaceuticals Inc | 19.67m | -36.18m | 12.80m | 233.00 | -- | -- | -- | 0.6506 | -2.98 | -2.98 | 1.62 | -1.85 | 0.6096 | 1.60 | 4.22 | 115,218.90 | -107.02 | -36.27 | -277.91 | -51.90 | 53.68 | 57.36 | -175.56 | -124.01 | 0.236 | -13.27 | -- | -- | -15.77 | 47.19 | -45.62 | -- | -55.67 | -- |
| Oxford Biodynamics PLC | 1.10m | -11.15m | 12.87m | 44.00 | -- | 5.26 | -- | 11.76 | -0.0096 | -0.0096 | 0.0008 | 0.0006 | 0.1085 | 2.22 | 1.21 | -- | -110.46 | -70.62 | -148.46 | -89.03 | 47.67 | -- | -1,018.54 | -1,715.57 | 0.8005 | -30.88 | 0.8208 | -- | 72.17 | 19.15 | 3.58 | -- | -11.79 | -- |
| Biofrontera AG | 20.22m | -1.86m | 12.89m | 76.00 | -- | 1.00 | -- | 0.6375 | -0.3607 | -0.3607 | 3.82 | 2.44 | 1.09 | 1.20 | 10.30 | 290,725.00 | -9.98 | -11.66 | -13.30 | -15.14 | 77.00 | 82.87 | -9.19 | -20.21 | 2.09 | 0.6033 | 0.035 | -- | -32.82 | -7.07 | -1,078.86 | -- | -35.31 | -- |
| Delta-Fly Pharma Inc | 0.00 | -7.90m | 13.18m | 13.00 | -- | 7.33 | -- | -- | -162.56 | -162.56 | 0.00 | 30.84 | 0.00 | -- | -- | 0.00 | -352.25 | -88.06 | -490.58 | -97.02 | -- | -- | -- | -1,051.54 | -- | -4,172.58 | 0.00 | -- | -- | -- | -20.41 | -- | -61.24 | -- |
| Voyageur Pharmaceuticals Ltd | 5.94k | -1.68m | 13.45m | -- | -- | 17.31 | -- | 2,264.69 | -0.0197 | -0.0197 | 0.00007 | 0.0081 | 0.0037 | 0.17 | 0.1428 | -- | -103.95 | -78.90 | -250.45 | -135.25 | -25.63 | -- | -28,307.25 | -- | 0.5081 | -- | 0.027 | -- | -- | -- | -21.99 | -- | -1.10 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Vulpes Investment Management Pte Ltd.as of 11 Nov 2025 | 618.54m | 14.42% |
| Pentwater Capital Management LPas of 11 Nov 2025 | 500.00m | 11.65% |
| KW Investment Management Ltd.as of 01 Jan 2026 | 416.13m | 9.70% |
| Unicorn Asset Management Ltd.as of 11 Nov 2025 | 278.46m | 6.49% |
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Jan 2026 | 123.38m | 2.88% |
| James Brearley & Sons Ltd.as of 01 Jan 2026 | 116.67m | 2.72% |
| Arbuthnot Latham & Co. Ltd.as of 01 Jan 2026 | 84.24m | 1.96% |
| IG Markets Ltd.as of 01 Jan 2026 | 43.16m | 1.01% |
| Cantor Fitzgerald Europeas of 04 Feb 2025 | 40.18m | 0.94% |
| Winterflood Securities Ltd (Market-Maker)as of 01 Jan 2026 | 33.08m | 0.77% |
